Evidence map›Paper›PMID 25902068›Full record

ArticlePLoS genetics2015

Ataxin-2 regulates RGS8 translation in a new BAC-SCA2 transgenic mouse model.

Warunee Dansithong, Sharan Paul, Karla P Figueroa, Marc D Rinehart, Shaina Wiest, Lance T Pflieger, Daniel R Scoles, Stefan M Pulst

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 98 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Targeted long-read sequencing captures CRISPR editing and AAV integration outcomes in brain.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  20. Neuro-respiratory pathology in spinocerebellar ataxia.Journal of the neurological sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Warunee DansithongDepartment of Neurology, University of Utah, Salt Lake City, Utah, United States of America.
Sharan PaulDepartment of Neurology, University of Utah, Salt Lake City, Utah, United States of America.
Karla P FigueroaDepartment of Neurology, University of Utah, Salt Lake City, Utah, United States of America.
Marc D RinehartDepartment of Neurology, University of Utah, Salt Lake City, Utah, United States of America.
Shaina WiestDepartment of Neurology, University of Utah, Salt Lake City, Utah, United States of America.
Lance T PfliegerDepartment of Neurology, University of Utah, Salt Lake City, Utah, United States of America.
Daniel R ScolesDepartment of Neurology, University of Utah, Salt Lake City, Utah, United States of America.
Stefan M PulstDepartment of Neurology, University of Utah, Salt Lake City, Utah, United States of America.
University of Utah · US

Funding

Spinocerebellar Ataxia Type 2 Gene and Gene ProductR37NS033123 · NINDS · UNIVERSITY OF UTAH · PI PULST, STEFAN M. · 2014 to 2020
$3.6M
SPINOCEREBELLAR ATAXIA TYPE 2--GENE AND GENE PRODUCTR01NS033123 · NINDS · UNIVERSITY OF UTAH · PI PULST, STEFAN M. · 1996 to 2012
$2.9M
Drug Discovery for Spinocerebellar Ataxia Type 2 (SCA2)RC4NS073009 · NINDS · UNIVERSITY OF UTAH · PI PULST, STEFAN M., SCOLES, DANIEL R · 2010 to 2010
$835k
Spinocerebellar Ataxia Type 2 Gene and Gene ProductR56NS033123 · NINDS · UNIVERSITY OF UTAH · PI PULST, STEFAN M. · 2013 to 2013
$473k
Antisense oligonucleotides for the treatment of spinocerebellar ataxia type 2R21NS081182 · NINDS · UNIVERSITY OF UTAH · PI PULST, STEFAN M., SCOLES, DANIEL R · 2013 to 2014
$408k
NINDS NIH HHS R01 NS033123NINDS NIH HHS R01NS33123NINDS NIH HHS R21 NS081182NINDS NIH HHS R21NS081182NINDS NIH HHS R37 NS033123NINDS NIH HHS R56 NS033123NINDS NIH HHS R56NS33123NINDS NIH HHS RC4 NS073009NINDS NIH HHS RC4NS073009
6 · The paper itself

Abstract

Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant disorder with progressive degeneration of cerebellar Purkinje cells (PCs) and other neurons caused by expansion of a glutamine (Q) tract in the ATXN2 protein. We generated BAC transgenic lines in which the full-length human ATXN2 gene was transcribed using its endogenous regulatory machinery. Mice with the ATXN2 BAC transgene with an expanded CAG repeat (BAC-Q72) developed a progressive cellular and motor phenotype, whereas BAC mice expressing wild-type human ATXN2 (BAC-Q22) were indistinguishable from control mice. Expression analysis of laser-capture microdissected (LCM) fractions and regional expression confirmed that the BAC transgene was expressed in PCs and in other neuronal groups such as granule cells (GCs) and neurons in deep cerebellar nuclei as well as in spinal cord. Transcriptome analysis by deep RNA-sequencing revealed that BAC-Q72 mice had progressive changes in steady-state levels of specific mRNAs including Rgs8, one of the earliest down-regulated transcripts in the Pcp2-ATXN2[Q127] mouse line. Consistent with LCM analysis, transcriptome changes analyzed by deep RNA-sequencing were not restricted to PCs, but were also seen in transcripts enriched in GCs such as Neurod1. BAC-Q72, but not BAC-Q22 mice had reduced Rgs8 mRNA levels and even more severely reduced steady-state protein levels. Using RNA immunoprecipitation we showed that ATXN2 interacted selectively with RGS8 mRNA. This interaction was impaired when ATXN2 harbored an expanded polyglutamine. Mutant ATXN2 also reduced RGS8 expression in an in vitro coupled translation assay when compared with equal expression of wild-type ATXN2-Q22. Reduced abundance of Rgs8 in Pcp2-ATXN2[Q127] and BAC-Q72 mice supports our observations of a hyper-excitable mGluR1-ITPR1 signaling axis in SCA2, as RGS proteins are linked to attenuating mGluR1 signaling.

Indexed as

Protein BiosynthesisAnimalsAtaxin-2CerebellumDisease Models, AnimalGene Expression RegulationHumansMiceMice, TransgenicMutationNeuronsPurkinje CellsRGS ProteinsSpinocerebellar AtaxiasAtaxin-2Atxn2 protein, mouseRGS8 protein, mouseRGS Proteins

Identifiers

PMID25902068
PMCPMC4406435
OpenAlexW2061108287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.